Severin Schwan, Roche CEO (Sebastien Bozon/AFP via Getty Images)
Updated: Roche hits the brakes on Alzheimer's trials after resurrected drug flunks PhIII
Is it finally time for Roche to give up on gantenerumab?
The Swiss pharma giant revealed that the anti-amyloid drug has failed two Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
